Plerixafor
From Wikipedia, the free encyclopedia
| Plerixafor | |
|---|---|
 |
|
 |
|
| IUPAC name | 1,1'-[1,4-Phenylenebis(methylene)]bis [1,4,8,11-tetraazacyclotetradecane] octohydrobromide dihydrate |
| Identifiers | |
| CAS number | [] |
| PubChem | |
| MeSH | |
| Properties | |
| Molecular formula | C28H54N8 |
| Molar mass | 502.782 g/mol |
| Except where noted otherwise, data are given for materials in their standard state (at 25 °C, 100 kPa) Infobox disclaimer and references |
|
Plerixafor (rINN and USAN, also known as JM 3100 and AMD3100) is a heterocyclic compound and potential fusion inhibitor. It is an antagonist (or perhaps more accurately a partial agonist) of the alpha-chemokine receptor CXCR4.
Contents |
[edit] Research
[edit] HIV
It was initially developed for potential use in the treatment of HIV, for its role in the blocking of CXCR4, a chemokine receptor which acts as a co-receptor for certain strains of HIV (along with the virus's main cellular receptor, CD4). However, clinical trials in patients with HIV-AIDS have to date shown relatively little useful anti-viral activity.
[edit] Mobilization of hematopoietic stem cells
However, the CXCR4 alpha-chemokine receptor and its ligand SDF-1 are also important in hematopoietic stem cell homing to the bone marrow and in hematopoietic stem cell quiescence. Plerixafor has been found to be a strong inducer of "mobilization" of hematopoietic stem cells from the bone marrow to the bloodstream as peripheral blood stem cells.[1]
Peripheral blood stem cell mobilization, which has become extremely important as a source of hematopoietic stem cells for transplantation over the past 10 to 15 years, is generally performed using the cytokine drug G-CSF, but is ineffective in around 15 to 20% of patients. AMD3100 offers clinical promise as a drug for peripheral blood stem cell mobilization, and has recently completed Phase 3 clinical trials.[2] It is not yet in routine clinical use.
[edit] References
- ^ Cashen A, Nervi B, DiPersio J (2007). "AMD3100: CXCR4 antagonist and rapid stem cell-mobilizing agent". Future Oncol 3 (1): 19-27. PMID 17280498.
- ^ (2007) "Plerixafor: AMD 3100, AMD3100, JM 3100, SDZ SID 791". Drugs R D 8 (2): 113-9. PMID 17324009.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
